Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Questcor Pharmaceuticals (QCOR) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.3%. By the end of trading, Questcor Pharmaceuticals fell 70 cents (-2.3%) to $30.10 on heavy volume. Throughout the day, 3.4 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in price between $29.40-$31.03 after having opened the day at $30.87 as compared to the previous trading day's close of $30.80. Other companies within the Health Care sector that declined today were: Aoxing Pharmaceutical Company (AXN), down 20%, Mela (MELA), down 16.1%, Opexa Therapeutics (OPXA), down 14.9%, and SunLink Health Systems (SSY), down 13.8%.

• EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $1.89 billion and is part of the drugs industry. The company has a P/E ratio of 10.3, below the S&P 500 P/E ratio of 17.7. Shares are up 20.8% year to date as of the close of trading on Tuesday. Currently there are six analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and one rates it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

• You can view the full Questcor Ratings Report.

On the positive front, Osiris Therapeutics (OSIR), up 35.3%, Vical Incorporated (VICL), up 15.4%, Astex Pharmaceuticals (ASTX), up 11.2%, and CytRx Corporation (CYTR), up 10.3%, were all gainers within the health care sector with Boston Scientific (BSX) being today's featured health care sector leader.

• Use our health care section to find sector-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

• Find other investment ideas from our top rated ETFs lists.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

 

For more information on Questcor Pharmaceuticals Inc. click any of the following:

• Questcor Pharmaceuticals Inc. Stock Price

• Questcor Pharmaceuticals Inc. Analyst Ratings

• Questcor Pharmaceuticals Inc. Key Stats & Profile

• Questcor Pharmaceuticals Inc. Earnings

• Questcor Pharmaceuticals Inc. Ratio Comparison

• Questcor Pharmaceuticals Inc. Growth Rates

• Questcor Pharmaceuticals Inc. Balance Sheet

• Questcor Pharmaceuticals Inc. Cash Flow

• Questcor Pharmaceuticals Inc. Income Statement